Holen Sie sich die Stockscreener-App
25.48
3.79%
0.93
Vorhandelsmarkt:
25.85
0.37
+1.45%
Schlusskurs vom Vortag:
$24.55
Offen:
$26
24-Stunden-Volumen:
2.48M
Relative Volume:
2.36
Marktkapitalisierung:
$2.23B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-11.63
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
+2.49%
1M Leistung:
+4.99%
6M Leistung:
+23.87%
1J Leistung:
-35.49%
1-Tages-Spanne:
$24.18
$26.01
1-Wochen-Bereich:
$24.04
$26.01
52-Wochen-Spanne:
$13.45
$40.25
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.48 | 2.15B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Analyzing IDEAYA Biosciences Inc. with risk reward ratio chartsJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Risk adjusted return profile for IDEAYA Biosciences Inc. analyzedMarket Trend Report & Growth-Oriented Investment Plans - Newser
Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan
How to escape a deep drawdown in IDEAYA Biosciences Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
Is IDEAYA Biosciences Inc. a cyclical or defensive stock2025 Valuation Update & Safe Entry Zone Tips - خودرو بانک
Will IDEAYA Biosciences Inc. continue its uptrend2025 EndofYear Setup & Proven Capital Preservation Methods - Newser
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionWeekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Comparing IDEAYA Biosciences Inc. in custom built stock radars2025 Institutional Moves & Short-Term Trading Alerts - Newser
Will IDEAYA Biosciences Inc. stock recover after recent drop2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performance2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Is IDEAYA Biosciences Inc. gaining market share2025 Trading Recap & Technical Analysis for Trade Confirmation - خودرو بانک
In Brief: Servier, IDEAYA Partner On Darovasertib For Uveal Melanoma - insights.citeline.com
Trend analysis for IDEAYA Biosciences Inc. this week2025 Major Catalysts & Weekly Sector Rotation Insights - Newser
Volatility clustering patterns for IDEAYA Biosciences Inc.2025 Fundamental Recap & AI Powered Trade Plan Recommendations - Newser
How to recover losses in IDEAYA Biosciences Inc. stockMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Will IDEAYA Biosciences Inc. benefit from geopolitical trendsRate Cut & Weekly Consistent Profit Watchlists - خودرو بانک
Servier pays big for ex-US darovasertib rights - The Pharma Letter
How high can IDEAYA Biosciences Inc. stock go2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Can IDEAYA Biosciences Inc. rally from current levelsStop Loss & Fast Momentum Entry Tips - Newser
Ideaya Biosciences Shares Jump Following $210 Million Licensing Deal with Servier - MSN
The Oncology Institute, Inc. shares fall 1.18% intraday as IDEAYA Biosciences announces positive trial data for darovasertib and crizotinib combination. - AInvest
IDEAYA Biosciences and Servier in-pact to develop eye cancer treatment - Seeking Alpha
Ideaya Biosciences stock surges after $210 million licensing deal with Servier - Investing.com
Precision Biosciences shares fall 1.22% premarket after IDEAYA Biosciences' partnership with Servier. - AInvest
Is this a good reentry point in IDEAYA Biosciences Inc.Inflation Watch & Weekly Top Stock Performers List - Newser
IDEAYA Biosciences' Strategic Licensing of Darovasertib: A Catalyst for Sustainable Growth and Value Creation - AInvest
IDEAYA Biosciences, Inc. Enters into License Agreement with Les Laboratoires Servier - MarketScreener
Analyzing drawdowns of IDEAYA Biosciences Inc. with statistical tools2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
IDEAYA Biosciences Soars 10.63% on Servier Partnership for Uveal Melanoma Treatment - AInvest
IDEAYA Biosciences Licenses Darovasertib to Servier - TipRanks
Real time breakdown of IDEAYA Biosciences Inc. stock performance2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
IDEAYA Biosciences receives $210mln upfront for darovasertib license, up to $320mln in milestones. - AInvest
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - WV News
What data driven models say about IDEAYA Biosciences Inc.’s future2025 AllTime Highs & Verified Momentum Stock Alerts - Newser
Is It Too Late to Sell IDEAYA Biosciences Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Is IDEAYA Biosciences Inc. a momentum stock2025 Price Momentum & AI Powered Market Trend Analysis - خودرو بانک
Can IDEAYA Biosciences Inc. expand into new marketsWeekly Trade Report & Weekly Stock Performance Updates - خودرو بانک
Backtesting results for IDEAYA Biosciences Inc. trading strategies2025 Top Decliners & AI Powered Trade Plan Recommendations - Newser
IDEAYA Biosciences Inc. Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - thegnnews.com
Measuring IDEAYA Biosciences Inc.’s beta against major indicesMarket Activity Report & Free Daily Entry Point Trade Alerts - Newser
Chart based analysis of IDEAYA Biosciences Inc. trendsQuarterly Portfolio Summary & Community Consensus Trade Alerts - Newser
Can IDEAYA Biosciences Inc. Outperform Peers After Recent Pullback getLinesFromResByArray error: size == 0 - thegnnews.com
Published on: 2025-08-31 12:35:43 - Newser
IDEAYA Biosciences Inc. stock daily chart insightsPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Weekly Gains Summary & Daily Chart Pattern Signals - Newser
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):